Sciwind Biosciences

Peptide therapeutics (obesity/metabolic)

Privately held: no public share price · China

Assets

(3 total)
3Total Assets
0Approved
1Phase 3 / Filed
2Phase 1–2 / Early
3Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 3
GLP-1 receptorPeptide
ObesityType 2 DiabetesOsteoarthritis
Phase 2
GLP-1 receptorPeptide
Obesity
Phase 1
GLP-1 receptorSmall molecule
Type 2 Diabetes

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (4)
January 2027 (1)
Ecnoglutide (VRB-101)Phase 1/2Overweight and/or Obesity, Weight Management
Est. primary completion 2027-01-05 · NCT07243171 · CT.gov ↗
What to watch
February 2027 (1)
ecnoglutidePhase 2Obesity, Weight Management
Est. primary completion 2027-02-27 · NCT07073417 · CT.gov ↗
What to watch
September 2027 (1)
ecnoglutidePhase 2Overweight , Obesity, Weight Management
Est. primary completion 2027-09-03 · NCT07929298 · CT.gov ↗
What to watch
December 2027 (1)
ecnoglutidePhase 3OSA - Obstructive Sleep Apnea, Obesity
Est. primary completion 2027-12-16 · NCT07387094 · CT.gov ↗
What to watch
2028 (3)
May 2028 (1)
ecnoglutidePhase 3Knee Osteoarthritis, Obesity
Est. primary completion 2028-05-31 · NCT07734311 · CT.gov ↗
What to watch
June 2028 (2)
ecnoglutidePhase 3Adolescents With Obesity, Adolescents With Overweight & Weight-related Comorbidities
Est. primary completion 2028-06-08 · NCT07836270 · CT.gov ↗
What to watch
ecnoglutidePhase 3OSA - Obstructive Sleep Apnea, Obesity
Est. primary completion 2028-06-19 · NCT07434050 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

23 August 2025Topline resultecnoglutideEECOH-2 (NCT05680129) Phase 3 met its primary endpoint
Sciwind Biosciences · Source ↗
2 January 2024Topline resultecnoglutideEECOH-1 (NCT05680155) Phase 3 met its primary endpoint
Sciwind Biosciences Co., Ltd. · Source ↗

Financial reports

No financial reports recorded.